Article published in Science Translational Medicine showing that cyclodextrin may reduce atherosclerosis attracts worldwide attention

Halvorsen (left) and Skjelland
Halvorsen (left) and Skjelland

Two OUS researchers - professor Bente Halvorsen from the Research Institute of Internal Medicine, and head physician Mona Skjelland from the Department of Neurology - have together with professor Terje Espevik and post doc Siril Bakke from NTNU participated in a large international research project where they have shown that cyclodextrin may reverse atherosclerosis. The study is run by a German research group led by professor Eicke Latz, and the results were recently published in Science Translational Medicine (journal impact factor 18.54). The research has also received widespread attention from various places, including two highly profiled articles in the major newspaper Wall Street Journal.
(story updated with more links to articles from various news sources, under "More")

Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation

Tom Hemming Karlsen
Tom Hemming Karlsen

A genetic analysis recently published in Nature Genetics (journal impact factor 29.35) sheds new light on the high comorbidity between primary sclerosing cholangitis (PSC) and inflammatory bowel disease.
Researchers from four large disease consortia, encompassing hundreds of researchers from 26 countries, joined forces to combine data from studies of their respective diseases, amounting to 52,262 patients and 34,213 healthy controls.
“This study is important because it creates a platform for understanding the molecular make-up of each disease, in the future enabling more specified treatment of chronic inflammatory disease”, says Tom Hemming Karlsen, coordinator of one of the participating consortia.